| RNAi and miRNA maturation
enhancer |
• Identification of enoxacin as a miRNA
enhancer from
screening of 2,000 US FDA drugs. |
2008 |
Jin et al.a
|
| • Experimental evidence of the involvement of TRBP
in
the SMER activity of enoxacin. |
| Anticancer agent |
• Identification of enoxacin
as an anticancer agent
in a panel of 12 cancer cell lines. |
2011 |
Esteller et al.b
|
| • Confirmation of its TRBP-dependent activity
and evidence
of TRBP/enoxacin binding by biophysical experiments. |
| Anticancer agent |
• Identification of the
ability of enoxacin to inhibit
the growth of prostate cancer cells through the reduction of HDAC1
and SIRT1 protein levels by miRNA modulation. |
2013 |
Jeronimo et al.c
|
| Anticancer agent |
• Identification of a
synergistic activity between enoxacin
and doxorubicin in treating Ewing sarcoma family tumors. |
2014 |
Stamenkovic et al.d
|
| Anticancer agent |
•
Identification of the ability of enoxacin to inhibit
the growth of melanoma cell lines. |
2017 |
Uldrijan et al.e
|
| • Experimental evidence that enoxacin increases
p53
protein levels by reducing MdmX transcripts through miRNA modulation. |
| • Demonstration that enoxacin is not involved
in human
topoisomerase inhibition. |
| Anticancer agent |
• Demonstration of the ability of enoxacin to inhibit
osteoclast formation by miRNA modulation. |
2018 |
Holliday et al.f
|
| Anticancer agent |
• Identification
of the ability of enoxacin to inhibit
the growth of a human thyroid cancer in an orthotopic mouse model. |
2019 |
Santisteban et
al.g
|
| • Experimental
evidence of the ability of enoxacin to
restore miRNA maturation at physiological levels in cells with low
levels of Dicer. |
| Anticancer agent |
• Identification of the ability of enoxacin to stimulate
diRNA production promoting DNA repair. |
2019 |
D’Adda di Fagagna et al.h
|
| Anti-ALS agent |
• Identification
of enoxacin as an anti-ALS agent by
its ability to modulate miRNA maturation. |
2015 |
Hornstein et al.i
|
| • Demonstration that enoxacin
delays neurological symptoms
in ALS mice. |
| Anti-ALS agent |
• Identification of the ability of enoxacin to increase
miRNA maturation in induced pluripotent stem cells (iPSCs). |
2018 |
Corti et al.j
|
| Anti-ALS agent |
• Identification
of the ability of enoxacin to increase
paraspeckle formation in neuroblastoma cells. |
2018 |
Buchman et al.k
|
| Antidepressant agent |
• Identification
of the ability of enoxacin to reduce
depressive behavior in rats by miRNA modulation. |
2014 |
Dwivedi et al.l
|
| Antiviral agent |
• Identification
of the ability of enoxacin to prevent
Zika virus infection in hNPC cells. |
2019 |
Qin et al.m
|
| • Experimental evidence that the antiviral activity
of enoxacin is dependent on the presence of Dicer. |
| Antiaging agent |
• Identification
of the ability of enoxacin to increase
lifespan in C. elegans by modulating miRNA maturation. |
2018 |
Mori et al.n
|
| • Experimental
evidence that lifespan-increasing activity
of enoxacin is ADAR-dependent. |
